Harnessing the Power of Regulatory T Cells to Modulate the Immune System
OVERVIEW
Regulatory T cells (Tregs) are a specialized subset of T cells that play a crucial role in maintaining immune homeostasis.
Unlike other immune cells that activate the immune response, Tregs function to control and suppress immune reactions, preventing excessive inflammation and autoimmunity. This ‘polypharmacy’ – the ability to act through multiple mechanisms – makes them a powerful therapeutic target.
OUR TREG PLATFORM
PTG-007 is an autologous and polyclonal cell therapy which has shown excellent safety and efficacy in T1D, MS, and GvHD.
PTG-007 Tregs represent a unique cell therapy platform where we can modify and engineer these safe and clinically validated cells to produce that can be modified and engineered to enhance its therapeutic potential and target specific diseases. PTG-007 offers several key advantages, including a strong safety profile and clinical experience in multiple autoimmune indications.
EXPERTISE
Immuthera’s Treg-based therapies, derived from the PTG-007 platform, have been evaluated in multiple clinical trials, demonstrating safety and promising efficacy in various autoimmune diseases. These trials have provided valuable insights into the therapeutic potential of Tregs and support our ongoing development efforts.
Clinical trials have demonstrated that PTG-007 is generally well-tolerated, with a favorable safety profile observed across studies.
In Type 1 Diabetes studies, Treg therapy has shown evidence of preserving insulin secretion, suggesting a potential to slow disease progression
Clinical data indicates that Treg treatment can extend the time of remission in patients, reducing the need for intensive insulin therapy
PTG-007 prevents progression for 12 months in Relapse Remitting Multiple Sclerosis (RRMS) when administered intrathecally. Measured by lack of progression in EDSS* and number and volume of plaques via MRI. *Expanded Disability Status Scale
LOOKING AHEAD: NOVEL TREG-BASED STRATEGIES
We are actively exploring novel approaches including CAR-Tregs, Allogeneic/Multi-edited CAR-Tregs, antigen-specific Tres, and mRNA Immunotherapies to further expand the therapeutic potential fo Tregs and address a broader range of diseases.
TREG CELL ENGINEERING
Chimeric antigen receptor (CAR) Tregs are engineered to express receptor that targets specific cells or tissues.
This technology allows us to direct Tregs to sites of inflammation and enhance their therapeutic activity. Our lead CAR-Treg programs are focused on addressing neuroinflammatory diseases such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).
NEXT GENERATION TREG CELL ENGINEERING
Next-Generation Cell Therapies for Autoimmune and Neuroinflammatory Diseases.
By combining Immuthera’s clinically validated PTG-007 platform with Antion’s modular gene editing technology, we are engineering a new class of CAR-Tregs designed to be used “off-the-shelf.” These allogeneic Tregs are enhanced through multiplex editing to closely mimic the phenotype and function of Tregs from Responder Patients in clinical trials. This next-generation approach allows for scalable, precise, and highly targeted Treg therapies capable of treating complex disorders such as Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).
PARTNERS
Immuthera benefits from a strong collaboration with PolTREG, a leader in Treg cell research and development.
This partnership allows us to leverage PolTREG’s extensive experience, proprietary technologies, and ongoing research to accelerate the development of novel Treg-based therapies and translate scientific discoveries into clinical breakthroughs.